NASDAQ : TRVI
Trevi Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 13.81 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.93B |
| Enterprise Value | 1.61B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 142.48M |
| Shares Outstanding | 142.48M |
| Shares Change (YoY) | +26.95% |
| Shares Change (QoQ) | +11.13% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 91.57% |
| Float | 118.32M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.01 |
| P/TBV Ratio | 6.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 37.28 |
| Quick Ratio | 36.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -19.66% |
| Return on Assets (ROA) | -13.82% |
| Return on Invested Capital (ROIC) | -14.28% |
| Return on Capital Employed (ROCE) | -18.51% |
| Weighted Average Cost of Capital (WACC) | 10.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 34 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -71,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +28.17% |
| 50-Day Moving Average | 14.69 |
| 200-Day Moving Average | 14.34 |
| Relative Strength Index (RSI) | 50.67 |
| Average Volume (20 Days) | 2,657,173 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 16.01M |
| Short Previous Month | 14.64M |
| Short % of Shares Out | 11.24% |
| Short % of Float | 13.53% |
| Short Ratio (days to cover) | 5.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.56M |
| Pretax Income | -51.18M |
| Net Income | -51.11M |
| EBITDA | -59.42M |
| EBIT | -59.56M |
| Earnings Per Share (EPS) | -$0.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 318.87M |
| Total Debt | 605,000 |
| Net Cash | 318.27M |
| Net Cash Per Share | $2.23 |
| Equity (Book Value) | 321.51M |
| Book Value Per Share | 2.26 |
| Working Capital | 316.97M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -52.63M |
| Capital Expenditures | -238,000 |
| Depreciation & Amortization | 137,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -52.87M |
| FCF Per Share | -$0.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.95% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.59% |
| FCF Yield | -2.74% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $28.18 |
| Price Target Difference | 107.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |